Fortress Biotech, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Fortress Biotech, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $63.26M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $57.68M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $84.51M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $75.74M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $68.79M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $45.60M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $36.63M | Apr 9, 2021 |
| FY2018 | Dec 31, 2018 | $8.99M | Mar 18, 2019 |
| FY2018 | Sep 30, 2018 | $5.17M | Mar 18, 2019 |
| FY2018 | Jun 30, 2018 | $6.82M | Mar 18, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $45.32M | Mar 16, 2018 |
| FY2017 | Sep 30, 2017 | $46.89M | Mar 16, 2018 |
| FY2017 | Jun 30, 2017 | $50.70M | Mar 16, 2018 |
| FY2017 | Mar 31, 2017 | $44.68M | Mar 16, 2018 |
| FY2017 | Dec 31, 2016 | $14.41M | Mar 16, 2018 |
| FY2017 | Sep 30, 2016 | $975.0K | Mar 16, 2018 |
| FY2017 | Jun 30, 2016 | $2.23M | Mar 16, 2018 |
| FY2017 | Mar 31, 2016 | $660.0K | Mar 16, 2018 |
| FY2016 | Dec 31, 2015 | $338.0K | Mar 16, 2017 |
| FY2016 | Sep 30, 2015 | $25.0K | Mar 16, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.82M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($46.00M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($60.64M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($86.58M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($64.70M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($46.53M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($39.96M) | Apr 9, 2021 |
| FY2018 | Dec 31, 2018 | ($24.88M) | Mar 18, 2019 |
| FY2018 | Sep 30, 2018 | ($16.64M) | Mar 18, 2019 |
| FY2018 | Jun 30, 2018 | ($21.61M) | Mar 18, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($70.22M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($110.38M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($142.34M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($203.56M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($188.54M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($94.27M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($110.82M) | Apr 9, 2021 |
| FY2018 | Dec 31, 2018 | ($41.21M) | Mar 18, 2019 |
| FY2018 | Sep 30, 2018 | ($33.38M) | Mar 18, 2019 |
| FY2018 | Jun 30, 2018 | ($32.21M) | Mar 18, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $106.07M | Mar 28, 2024 |
| FY2023 | Dec 31, 2022 | $134.88M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $128.87M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $64.11M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $81.33M | Apr 9, 2021 |
| FY2019 | Dec 31, 2018 | $87.38M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $48.32M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $35.13M | Mar 16, 2018 |
| FY2017 | Dec 31, 2015 | $29.81M | Mar 16, 2018 |
| FY2015 | Dec 31, 2014 | $10.24M | Mar 15, 2016 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $96.40M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $87.73M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $90.98M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $113.66M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $86.84M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $61.17M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $55.59M | Apr 9, 2021 |
| FY2019 | Dec 31, 2018 | $53.37M | Mar 16, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($65.78M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($80.19M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($128.23M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($179.40M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($116.54M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($83.68M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($94.96M) | Apr 9, 2021 |
| FY2019 | Dec 31, 2018 | ($98.85M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($81.31M) | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($45.81M) | Mar 16, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $63.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.72M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $4.57M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.93M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $2.35M | Apr 9, 2021 |
| FY2019 | Dec 31, 2018 | $7.08M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $648.0K | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $6.37M | Mar 16, 2018 |
| FY2017 | Dec 31, 2015 | $283.0K | Mar 16, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $185.55M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $144.22M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $167.53M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $294.30M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $396.50M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $333.41M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $226.42M | Apr 9, 2021 |
| FY2019 | Dec 31, 2018 | $140.99M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $245.95M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $170.73M | Mar 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $123.37M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $145.87M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $165.94M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $244.28M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $170.63M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $136.41M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $153.89M | Apr 9, 2021 |
| FY2019 | Dec 31, 2018 | $121.25M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $125.45M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $87.76M | Mar 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $49.87M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $22.74M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $22.54M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $41.72M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $108.67M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $100.34M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $26.22M | Apr 9, 2021 |
| FY2019 | Dec 31, 2018 | $1.85M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $52.57M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $38.50M | Mar 16, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $18.65M | Mar 16, 2018 |
| FY2017 | Dec 31, 2016 | $18.65M | Mar 16, 2018 |
| FY2016 | Dec 31, 2015 | $0 | Mar 16, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($734.05M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($740.87M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($694.87M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($634.23M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($547.46M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($482.76M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($436.23M) | Apr 9, 2021 |
| FY2019 | Dec 31, 2018 | ($396.27M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($312.13M) | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($245.25M) | Mar 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $79.38M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $57.26M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $80.93M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $178.27M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $305.74M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $233.35M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $136.86M | Apr 9, 2021 |
| FY2019 | Dec 31, 2018 | $65.51M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $94.95M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $88.29M | Mar 16, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.42M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $57.96M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $60.86M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $91.73M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $42.94M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $51.68M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $84.66M | Apr 9, 2021 |
| FY2019 | Dec 31, 2018 | $84.41M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $67.54M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $30.22M | Mar 16, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (8) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (15) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (8) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (15) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 31.36M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 27.91M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 15.09M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 7.37M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 101.44M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 94.88M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | 74.03M | Apr 9, 2021 |
| FY2019 | Dec 31, 2018 | 57.85M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | 50.99M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | 48.93M | Mar 16, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $664.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $694.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $736.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $749.0K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $749.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $237.0K | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Apr 9, 2021 |